Publications by authors named "A Lucchesi"
Myeloproliferative neoplasms represent a group of clonal hematopoietic disorders of which myelofibrosis (MF) is the most aggressive. In the context of myeloid neoplasms, there is a growing recognition of the dysregulation of immune response and T-cell function as significant contributors to disease progression and immune evasion. We investigated cytotoxic T-cell exhaustion in MF to restore immune response against malignant cells.
View Article and Find Full Text PDFThe discovery of driver mutations in myeloproliferative neoplasms has significantly contributed to the management of patients with essential thrombocythaemia (ET). High-quality evidence has started to pave the way for targeted therapy. The review by Ferrer-Marín et al.
View Article and Find Full Text PDFBackground: Dysbiotic biliary bacterial profile is reported in cancer patients and is associated with survival and comorbidities, raising the question of its effect on the influence of anticancer drugs and, recently, the suggestion of perichemotherapy antibiotics in pancreatic cancer patients colonized by the Escherichia coli and Klebsiella pneumoniae.
Objective: In this study, we investigated the microbial communities that colonize tumours and which bacteria could aid in diagnosing pancreatic and biliary cancer and managing bile-colonized patients.
Methods: A retrospective study on positive bile cultures of 145 Italian patients who underwent cholangiopancreatography with PC and EPC cancer hospitalized from January 2006 to December 2020 in a QA-certified academic surgical unit were investigated for aerobic/facultative-anaerobic bacteria and fungal organisms.
Article Synopsis
- Rearranged neoplasms are rare blood cancers, with about 80 cases, involving myeloid and lymphoid leukemias, linked to gene translocations that activate partner genes.
- A case of a 54-year-old woman revealed a rare cryptic insertion of the gene associated with such neoplasms, initially diagnosed as idiopathic hypereosinophilic syndrome.
- Advanced sequencing techniques led to the identification of specific fusion transcripts, confirming the diagnosis and prompting effective treatment with imatinib mesylate, resulting in lasting positive outcomes after over a year.